Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sanofi Consumer Healthcare India Debt-to-Equity?
Sanofi Consumer Healthcare IndiaNSE:SANOFICONR +1.10%24 Debt-to-Equity is 0.06 as of Jun. 2026, which is 14% below its 10-year median of 0.07. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 814 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 80.59% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sanofi Consumer Healthcare India's Debt-to-Equity or its related term are showing as below:
NSE:SANOFICONR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.07 Max: 0.11
Current: 0.06
During the past 3 years, the highest Debt-to-Equity Ratio of Sanofi Consumer Healthcare India was 0.11. The lowest was 0.06. And the median was 0.07.
NSE:SANOFICONR's Debt-to-Equity is ranked better than 80.59% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs NSE:SANOFICONR: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sanofi Consumer Healthcare India Debt-to-Equity Related Terms
Sanofi Consumer Healthcare India Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India Debt-to-Equity Chart
NSE:SANOFICONR vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a Debt-to-Equity of 0.06 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sanofi Consumer Healthcare India and its competitors. This is 14% below median its historical median of 0.07. Over the past decade, Sanofi Consumer Healthcare India's Debt-to-Equity has ranged from 0.06 to 0.11. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #158 out of 814 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Sanofi Consumer Healthcare India's Debt-to-Equity too high?
Sanofi Consumer Healthcare India's current Debt-to-Equity of 0.06 is 14% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.11. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Sanofi Consumer Healthcare India's value of 0.06 is 78.6% below this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #158 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #158 out of 814 companies for Debt-to-Equity. This places Sanofi Consumer Healthcare India in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Sanofi Consumer Healthcare India's value of 0.06 is 78.6% below this benchmark. Historically, Sanofi Consumer Healthcare India's own Debt-to-Equity has ranged from 0.06 to 0.11 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.28, Sanofi Consumer Healthcare India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current Debt-to-Equity of 0.06 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current Debt-to-Equity is 0.06, which is 14% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current Debt-to-Equity of 0.06. The current Debt-to-Equity is 0.06, which is 14% below median its 10-year median of 0.07 and 78.6% below the Drug Manufacturers industry median of 0.28. Sanofi Consumer Healthcare India's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current Debt-to-Equity is 0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
24GF Score
Get the complete analysis for NSE:SANOFICONR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
